CD274 and prostate carcinoma: A negative correlation between EZH2 and PD-L1 expression was observed in hepatocellular carcinoma and prostate cancer, which may result from the upregulation of H3K27me3 levels in the promoters of CD274 and IRF1 (66, 68).